These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2724144)

  • 1. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH; van der Wart JH; Brugman M; Breimer DD
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.
    Schellens JH; Ghabrial H; van der Wart HH; Bakker EN; Wilkinson GR; Breimer DD
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):520-8. PubMed ID: 1934865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of aging on the metabolism of simultaneously administered hexobarbital enantiomers and antipyrine before and after phenobarbital induction in male rats: a longitudinal study.
    Groen K; Breimer DD; Jansen EJ; van Bezooijen CF
    J Pharmacol Exp Ther; 1994 Feb; 268(2):531-6. PubMed ID: 8113964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats.
    Teunissen MW; Van Graft M; Vermeulen NP; Breimer DD
    Xenobiotica; 1983 Aug; 13(8):497-502. PubMed ID: 6649682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
    Inaba T; Jurima M; Nakano M; Kalow W
    Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.
    Horai Y; Ishizaki T; Eichelbaum M; Hashimoto K; Chiba K; Dengler HJ
    Xenobiotica; 1988 Sep; 18(9):1077-84. PubMed ID: 3227705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    Drøhse A; Bathum L; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene.
    Groen K; Breimer DD; van Bezooijen CF
    Drug Metab Dispos; 1992; 20(4):502-6. PubMed ID: 1356725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.
    Adedoyin A; Aarons L; Houston JB
    Drug Metab Dispos; 1987; 15(1):127-32. PubMed ID: 2881749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
    Fromm MF; Hofmann U; Griese EU; Mikus G
    Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of cigarette smoke on antipyrine metabolite formation in rats.
    Nakagawa A; Chiba K; Ishizaki T; Nakamura K
    Res Commun Chem Pathol Pharmacol; 1983 Sep; 41(3):473-91. PubMed ID: 6635330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of enzyme induction on polymorphic sparteine oxidation.
    Eichelbaum M; Mineshita S; Ohnhaus EE; Zekorn C
    Br J Clin Pharmacol; 1986 Jul; 22(1):49-53. PubMed ID: 3741726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
    Dahlqvist R; Bertilsson L; Birkett DJ; Eichelbaum M; Säwe J; Sjöqvist F
    Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of concomitant administration of cimetidine and phenobarbital on antipyrine elimination and metabolite formation.
    Sonne J; Døssing M; Poulsen HE; Pilsgaard H; Rasmussen B; Loft S
    Int J Clin Pharmacol Ther Toxicol; 1987 Apr; 25(4):194-6. PubMed ID: 3583468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats.
    van der Graaff M; Vermeulen NP; Joeres RP; Vlietstra T; Breimer DD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):459-65. PubMed ID: 6631725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.